July short interest fell sharply for Guided Therapeutics, Prio, and Q.E.P. Co., with each showing multi-fold declines from the prior month, while Obra Opportunistic Structured Products ETF experienced a substantial rise in short interest. Guided Therapeutics saw its short interest drop by 92.7% to 1,437 shares as of mid-July, and its stock traded around $0.25 amid light volume. Prio also posted a large July decline in short interest, down 95.3% to 260 shares, as the stock traded near its 52-week range and a Zacks upgrade to hold was noted. Q.E.P. Co. reported a dramatic 99.6% reduction in short interest to 2 shares, with earnings and revenue disclosed for the quarter. In contrast, Obra’s short interest surged by 1,396.7% to 4,056 shares, though the ETF’s price remained flat around $10.13, highlighting divergent investor sentiment across equities and fixed-income-focused funds.